New Delhi, February 01, 2023: The Budget 2023-24 has showcased immense focus on the Indian pharma industry with announcement of the new R&D program. To support this, the exponential increase in allocation towards such schemes will be a driving force in strengthening India’s global position not only as a manufacturing hub but also promoting India as a prime investment location for pharma R&D.
The announcement of three artificial intelligence centers of excellence to enable ‘Make AI for India’ and ‘Make AI work for India’ will be a huge step forward in addressing future-ready infrastructure requirements, skilled labor, and overall industry innovation. Furthermore, the emphasis on medical device skilling is a move in the right direction for the expansion of the healthcare-pharma ecosystem” commented Mr. Shyamakant Giri, Managing Director & President, India Business and Emerging Markets, Amneal Healthcare.
Corporate Comm India (CCI Newswire)
